3.2 DSM-5-TR Substance Use Disorders: Criteria, Specifiers, and Neurobiology of Addiction
Key Takeaways
- The DSM-5-TR eliminated the historical DSM-IV distinction between substance abuse and substance dependence, establishing a unified dimensional Substance Use Disorder (SUD) framework based on 11 diagnostic criteria.
- The 11 criteria are organized into 4 functional clusters: Impaired Control (Criteria 1-4), Social Impairment (Criteria 5-7), Risky Use (Criteria 8-9), and Pharmacological Criteria (Criteria 10-11: Tolerance and Withdrawal).
- SUD severity is graded dimensionally based on the number of criteria met within a 12-month period: Mild (2-3 criteria), Moderate (4-5 criteria), and Severe (6 or more criteria).
- Remission specifiers require complete absence of all SUD criteria (except craving) over specific timeframes: Early Remission (3 to 12 months) and Sustained Remission (12 months or longer).
- The neurobiology of addiction is conceptualized as a 3-stage recurring cycle: Binge/Intoxication (basal ganglia/VTA-NAc dopamine surge), Withdrawal/Negative Affect (extended amygdala/CRF stress recruitment), and Preoccupation/Anticipation (prefrontal cortex executive dysregulation).
DSM-5-TR Substance Use Disorders: Criteria, Specifiers, and Neurobiology of Addiction
In 2013, the American Psychiatric Association published the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), which was subsequently updated in 2022 with text revisions (DSM-5-TR). A major paradigm shift in addiction medicine was the complete elimination of the categorical dichotomy between "Substance Abuse" and "Substance Dependence" that had defined DSM-III-R and DSM-IV.
In its place, DSM-5-TR established a single, unified continuum of Substance Use Disorder (SUD) for each distinct drug class (e.g., Alcohol Use Disorder, Opioid Use Disorder, Stimulant Use Disorder). Addiction professionals must demonstrate flawless diagnostic acumen regarding the 11 core diagnostic criteria, the four functional symptom clusters, severity stratification, remission specifiers, and the underlying neurobiological mechanisms that drive chronic addictive disease.
1. The DSM-5-TR 11 Diagnostic Criteria and Functional Clusters
A diagnosis of a Substance Use Disorder is established when an individual exhibits a problematic pattern of substance use leading to clinically significant impairment or distress, manifested by at least 2 of the 11 criteria occurring within a 12-month period.
+-----------------------------------------------------------------------------------------+
| THE 11 DSM-5-TR SUBSTANCE USE DISORDER CRITERIA |
| |
| CLUSTER I: IMPAIRED CONTROL (Criteria 1 - 4) |
| 1. Larger amounts or longer duration than originally intended (Loss of Control) |
| 2. Persistent desire or unsuccessful efforts to cut down or control use (Failed Cut) |
| 3. Great deal of time spent obtaining, using, or recovering from substance (Time) |
| 4. Craving, or a strong desire or urge to use the substance (Craving - NEW in DSM-5) |
| |
| CLUSTER II: SOCIAL IMPAIRMENT (Criteria 5 - 7) |
| 5. Recurrent use resulting in failure to fulfill major role obligations (Role Failure)|
| 6. Continued use despite persistent/recurrent social or interpersonal problems (Conflict) |
| 7. Important social, occupational, or recreational activities given up/reduced (Sacrifice)|
| |
| CLUSTER III: RISKY USE (Criteria 8 - 9) |
| 8. Recurrent substance use in situations in which it is physically hazardous (Hazard) |
| 9. Continued use despite knowledge of physical or psychological problem caused/worsened|
| |
| CLUSTER IV: PHARMACOLOGICAL CRITERIA (Criteria 10 - 11) |
| 10. Tolerance (need for increased amounts OR diminished effect with same amount) |
| 11. Withdrawal (characteristic withdrawal syndrome OR substance taken to relieve/avoid)|
+-----------------------------------------------------------------------------------------+
Comprehensive Breakdown of the 11 Criteria:
| Cluster | Criterion # & DSM-5-TR Description | Clinical Manifestations & Case Examples |
|---|---|---|
| Impaired Control | 1. Larger / Longer: Substance is often taken in larger amounts or over a longer period than was intended. | Client plans to have 'one beer' after work but drinks a 12-pack until unconscious; promises partner to return in 30 minutes but disappears for two days. |
| Impaired Control | 2. Inability to Cut Down: Persistent desire or unsuccessful efforts to cut down or control substance use. | Client makes multiple sincere vows to quit using methamphetamine, throws away pipes/paraphernalia, but repeatedly resumes use within days. |
| Impaired Control | 3. Time Spent: Great deal of time spent in activities necessary to obtain the substance, use the substance, or recover from its effects. | Client spends 6 hours daily driving across town to multiple dealers, engaging in binge use, and spending entire weekends in bed recovering from hangovers. |
| Impaired Control | 4. Craving: Craving, or a strong desire or urge to use the substance. (Added in DSM-5; replaces DSM-IV recurrent legal problems). | Intense, intrusive, obsessive thoughts about using triggered by environmental cues (e.g., passing former dealer's street, smelling alcohol, experiencing anger). |
| Social Impairment | 5. Role Failure: Recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home. | Repeated absences from work due to intoxication or severe hangovers leading to job termination; chronic neglect of children's basic needs and nutrition. |
| Social Impairment | 6. Interpersonal Problems: Continued substance use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by use. | Arguments with spouse regarding intoxication leading to domestic disputes, marital separation, or physical altercations with peers while intoxicated. |
| Social Impairment | 7. Activities Given Up: Important social, occupational, or recreational activities are given up or reduced because of substance use. | Individual ceases lifelong hobbies (e.g., playing music, coaching child's sports team, attending church) to spend time drinking alone or with using peers. |
| Risky Use | 8. Physically Hazardous: Recurrent substance use in situations in which it is physically hazardous. | Operating motor vehicles while intoxicated, operating industrial power machinery while using benzodiazepines, swimming or caring for infants while high. |
| Risky Use | 9. Use Despite Harm: Substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem likely caused or exacerbated by the substance. | Continued alcohol consumption despite a physician diagnosis of alcoholic cirrhosis and bleeding esophageal varices; continuing cocaine use despite severe paranoia. |
| Pharmacological | 10. Tolerance: A need for markedly increased amounts of substance to achieve intoxication or desired effect, OR a markedly diminished effect with continued use of the same amount. | Individual who initially achieved euphoria with 10 mg of oxycodone now requires 80 mg daily to feel normal; drinking a fifth of vodka without showing overt motor ataxia. |
| Pharmacological | 11. Withdrawal: The characteristic withdrawal syndrome for the substance, OR the substance (or closely related substance) is taken to relieve or avoid withdrawal symptoms. | Experiencing gross tremors, diaphoresis, nausea, and tachycardia 8 hours after last alcohol drink; taking morning 'eye-opener' drink or illicit benzodiazepine to stop shakes. |
[!IMPORTANT] Medical Supervision Exception for Pharmacological Criteria: Criteria 10 (Tolerance) and 11 (Withdrawal) are NOT counted as positive criteria toward the diagnosis of a Substance Use Disorder when the individual is taking prescribed medications (such as opioid analgesics, sedative-hypnotics, or stimulants) strictly under appropriate medical supervision. Physiological dependence is an expected, normal biological adaptation to long-term therapeutic pharmacotherapy and does not inherently constitute addiction.
2. DSM-5-TR Severity Stratification and Diagnostic Specifiers
DSM-5-TR replaces the old binary abuse/dependence model with a dimensional severity metric determined by the total count of positive diagnostic criteria met over the past 12 months.
+-----------------------------------------------------------------------------------------+
| DSM-5-TR SUD SEVERITY CONTINUUM |
| |
| [NO DIAGNOSIS] --> 0 to 1 Criterion (Sub-clinical / At-risk use) |
| | |
| v |
| [MILD SUD] --> 2 to 3 Criteria Met |
| | |
| v |
| [MODERATE SUD] --> 4 to 5 Criteria Met |
| | |
| v |
| [SEVERE SUD] --> 6 or MORE Criteria Met (Corresponds to severe dependence) |
+-----------------------------------------------------------------------------------------+
Remission Specifiers:
Remission specifiers can only be applied after full diagnostic criteria for a substance use disorder were previously met, and the individual subsequently meets NONE of the criteria (with the single permitted exception of Criterion 4: Craving):
- In Early Remission: Full criteria for SUD have not been met for at least 3 months but less than 12 months.
- In Sustained Remission: Full criteria for SUD have not been met at any time during a period of 12 months or longer.
+-----------------------------------------------------------------------------------------+
| COURSE AND REMISSION SPECIFIERS |
| |
| 0 Months 3 Months 12 Months Ongoing |
| +--------------------+------------------------------------+----------------------> |
| | ACTIVE SUD | IN EARLY REMISSION | IN SUSTAINED REMISSION |
| | (Full criteria met)| (No criteria met except craving) | (No criteria met >12 mos) |
| +--------------------+------------------------------------+----------------------> |
+-----------------------------------------------------------------------------------------+
Additional Environmental and Therapeutic Specifiers:
- In a Controlled Environment: Applied when the individual is living in an environment where access to the substance is strictly restricted (e.g., closely supervised correctional institutions, locked psychiatric units, residential recovery communities).
- On Maintenance Therapy: Applied when the individual is taking an approved agonist/partial agonist medication (e.g., methadone, buprenorphine, nicotine replacement) or antagonist (e.g., naltrexone) and no criteria for SUD are met for that class (except tolerance/withdrawal to the agonist medication).
3. Neurobiology of Addiction: The Three-Stage Cycle & Brain Circuitry
Addiction is defined by the American Society of Addiction Medicine (ASAM) and the National Institute on Drug Abuse (NIDA) as a primary, chronic, relapsing brain disease characterized by compulsive substance seeking and use despite devastating consequences. Decades of neuroimaging and neurobiological research (spearheaded by George Koob, Nora Volkow, and colleagues) demonstrate that chronic substance use hijacks core neural circuits governing reward, emotion, memory, and executive decision-making.
+-----------------------------------------------------------------------------------------+
| THE THREE-STAGE NEUROBIOLOGICAL ADDICTION CYCLE |
| |
| STAGE 1: BINGE / INTOXICATION |
| • Neuroanatomy: BASAL GANGLIA (Nucleus Accumbens & Dorsal Striatum) |
| • Neurotransmitters: DOPAMINE & OPIOID PEPTIDES |
| • Mechanism: Massive dopamine surge in Nucleus Accumbens creates intense euphoria and |
| incentive salience ('wanting'). Transition to Dorsal Striatum drives automated, |
| compulsive habit formation. |
| | |
| v |
| STAGE 2: WITHDRAWAL / NEGATIVE AFFECT (THE 'ANTI-REWARD' SYSTEM) |
| • Neuroanatomy: EXTENDED AMYGDALA (Central Amygdala & BNST) |
| • Neurotransmitters: CORTICOTROPIN-RELEASING FACTOR (CRF), DYNORPHIN, NOREPINEPHRINE |
| • Mechanism: Downregulation of dopamine D2 receptors produces severe anhedonia. |
| Recruitment of brain stress systems generates intense anxiety, dysphoria, and |
| hyperalgesia, driving negative reinforcement (using to escape emotional pain). |
| | |
| v |
| STAGE 3: PREOCCUPATION / ANTICIPATION ('CRAVING') |
| • Neuroanatomy: PREFRONTAL CORTEX (Dorsolateral PFC, ACC, OFC) & INSULA / HIPPOCAMPUS |
| • Neurotransmitters: GLUTAMATE |
| • Mechanism: Executive dysfunction impairs top-down inhibitory control ('Go/Stop' |
| deficits). Conditioned cues trigger glutamate surges from hippocampus/amygdala |
| to prefrontal cortex, driving obsessive craving and relapse. |
+-----------------------------------------------------------------------------------------+
Core Neurocircuitry and Neurochemical Architecture:
| Brain Structure | Primary Neurotransmitters | Normal Physiological Role | Pathological Alteration in Addiction |
|---|---|---|---|
| Ventral Tegmental Area (VTA) → Nucleus Accumbens (NAc) | Dopamine, Opioid Peptides | Mesolimbic Reward Pathway: Signals biological salience, natural rewards (food, sex), and reinforces survival behaviors. | Addictive substances cause artificial, supra-physiological dopamine surges (2x to 10x natural rewards), cementing profound incentive salience. |
| Dorsal Striatum (Caudate & Putamen) | Dopamine, Acetylcholine | Motor coordination, stimulus-response habit learning, behavioral automation. | Encodes substance-seeking routines into automatic motor habits that persist even when conscious pleasure is absent. |
| Extended Amygdala (Central Amygdala, BNST) | Corticotropin-Releasing Factor (CRF), Dynorphin, Norepinephrine | Coordinates emotional responses to acute stress, threat detection, and fear conditioning. | Chronic drug use creates an overactive Anti-Reward System; during withdrawal, CRF surges cause profound dysphoria, restlessness, and emotional pain. |
| Prefrontal Cortex (dlPFC, OFC, Anterior Cingulate) | Glutamate, GABA, Dopamine | Executive functioning, impulse control, working memory, risk-benefit appraisal, self-monitoring. | Hypofrontality: Downregulation of prefrontal activity compromises top-down inhibitory control, rendering the individual unable to suppress urges. |
| Hippocampus & Basolateral Amygdala | Glutamate | Contextual memory consolidation and emotional cue associations. | Forms indelible conditioned memories linking drug cues/environments with reward, triggering intense craving upon re-exposure. |
| Insular Cortex (Insula) | Interoceptive processing | Conscious awareness of internal bodily states, cravings, and gut feelings. | Hyperactivity during cue presentation amplifies conscious subjective experience of craving and somatic withdrawal distress. |
4. Differential Diagnosis: Primary SUD vs. Substance-Induced Disorders
A critical diagnostic competency tested on the NCAC examination is distinguishing Primary Mental Disorders from Substance-Induced Mental Disorders and expected physiological intoxication/withdrawal states.
+-----------------------------------------------------------------------------------------+
| PRIMARY VS. SUBSTANCE-INDUCED DIFFERENTIAL |
| |
| DIAGNOSTIC CRITERIA SUBSTANCE-INDUCED DISORDER PRIMARY MENTAL DISORDER |
| +-------------------------+-----------------------------+---------------------------+ |
| | Timing of Onset | Develops during/within 1 mo | Preceded substance use | |
| | | of intoxication/withdrawal | onset (independent history| |
| | Resolution Timeline | Substantially remits within | Persists > 1 month after | |
| | | 1 month of complete sobriety| acute withdrawal ceases | |
| | Family History | Strong SUD family history | Strong psychiatric history| |
| | Substance-Symptom Match | Compatible with drug pharma | Incompatible with drug | |
| | | (e.g., stimulant psychosis) | pharmacology | |
| +-------------------------+-----------------------------+---------------------------+ |
+-----------------------------------------------------------------------------------------+
Clinical Rules for Establishing Substance-Induced Diagnoses (DSM-5-TR):
- Temporal Association: The psychiatric symptoms (e.g., psychosis, major depression, panic attacks) must develop during or within 1 month of significant substance intoxication or withdrawal.
- Pharmacological Plausibility: The ingested substance must be physiologically capable of producing the specific psychiatric syndrome (e.g., cocaine/methamphetamine inducing paranoid psychosis; alcohol/benzodiazepine withdrawal inducing panic and severe anxiety; chronic alcohol/opioid dependence inducing major depressive episodes).
- Exclusion of Independent Primary Disorder: The symptoms are NOT considered substance-induced if:
- The psychiatric disorder preceded the onset of severe substance use.
- The symptoms persist for a substantial period of time (typically more than 1 month) after the cessation of acute withdrawal or severe intoxication.
- The client has a documented history of recurrent primary psychiatric episodes during periods of extended, verified abstinence.
A 34-year-old client reports consuming 12 to 18 alcoholic drinks daily for the past 5 years. Over the previous 12 months, the client experienced recurrent blackouts, failed three attempts to quit drinking, lost custody of their children due to intoxication, continued drinking despite bleeding gastric ulcers, experienced severe hand tremors upon awakening, and reported severe cravings whenever walking past a liquor store. What is the correct DSM-5-TR diagnostic classification and severity specifier?
A client with a 10-year history of severe heroin use has been enrolled in a certified Opioid Treatment Program (OTP) receiving daily prescribed methadone for the past 7 months. During this 7-month period, the client has maintained negative illicit drug toxicology screens, gained steady employment, and meets zero SUD diagnostic criteria. Which DSM-5-TR specifiers should the counselor apply?
In the neurobiological three-stage cycle of addiction described by Koob and Volkow, what neuroanatomical structure and neurochemical adaptation are primarily responsible for the severe dysphoria, anxiety, and anhedonia experienced during the Withdrawal/Negative Affect stage?